Use of propafenone for conversion of chronic atrial fibrillation in horses

American Journal of Veterinary Research

Volumn 70, Issue 2, 2009, Pages 223-227

  de Clercq, Dominique ^a   van Loon, Gunther ^a   Tavernier, Rene ^b   Verbesselt, Rene ^c   Deprez, Piet ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PROPAFENONE; QUINIDINE SULFATE;

ANIMAL EXPERIMENT; ARTICLE; BOLUS INJECTION; CARDIOVERSION; CHRONIC DISEASE; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG EFFICACY; ELECTROCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HORSE; NONHUMAN; SINUS RHYTHM; TREATMENT FAILURE;

ANALYSIS OF VARIANCE; ANIMALS; ATRIAL FIBRILLATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HORSE DISEASES; HORSES; INJECTIONS, INTRAVENOUS; PROPAFENONE;

ANIMALIA; EQUIDAE;

EID: 60749092582     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.70.2.223     Document Type: Article

References (42)

1. Deem DA, Fregin GF. Atrial fibrillation in horses: a review of 106 clinical cases, with consideration of prevalence, clinical signs, and prognosis. J Am Vet Med Assoc 1982;180:261-265.
2. Reef VB, McGuirk SM. Diseases of the cardiovascular system. Atrial fibrillation. In: Smith BP, ed. Large animal internal medicine. St Louis: Mosby, 2002;471-474.
3. Reef VB, Levitan CW, Spencer PA. Factors affecting prognosis and conversion in equine atrial fibrillation. J Vet Intern Med 1988;2:1-6.
4. van Loon G, Deprez P, Duytschaever M, et al. Effects of experimental chronic atrial fibrillation in equines. In: van Loon G, ed. Atrial pacing and experimental atrial fibrillation in equines. Ghent, Belgium: Ghent University, 2001;162-206.
5. Reef VB, Reimer JM, Spencer PA. Treatment of atrial fibrillation in horses: new perspectives. J Vet Intern Med 1995;9:57-67.
6. Ohmura H, Nukada T, Mizuno Y, et al. Safe and efficacious dosage of flecainide acetate for treating equine atrial fibrillation. J Vet Med Sci 2000;62:711-715.
7. van Loon G, Blissitt KJ, Keen JA, et al. Use of intravenous flecainide in horses with naturally-occurring atrial fibrillation. Equine Vet J 2004;36:609-614.
8. van Loon G. Methods of treatment and new management techniques in horses with AF, in Proceedings. Autumn Meet Vet Cardiovasc Soc 2003;2-17.
9. De Clercq D, van Loon G, Baert K, et al. Intravenous amiodarone treatment in horses with chronic atrial fibrillation. Vet J 2006;172:129-139.
10. De Clercq D, van Loon G, Baert K, et al. Effects of an adapted intravenous amiodarone treatment protocol in horses with atrial fibrillation. Equine Vet J 2007;39:344-349.
11. McGurrin KMJ, Physick-Sheard PW, Kenney DG, et al. Transvenous electrical cardioversion in equine atrial fibrillation: technique and successful treatment of 3 horses. J Vet Intern Med 2003;5:715-718.
12. Frye MA, Selders CG, Mama KR, et al. Use of biphasic electrical cardioversion for treatment of idiopathic atrial fibrillation in two horses. J Am Vet Med Assoc 2002;220:1039-1045.
13. McGurrin MKJ, Physick-Sheard PW, Kenney DG, et al. Transvenous electrical cardioversion of equine atrial fibrillation: technical considerations. J Vet Intern Med 2005;19:695-702.
14. McGurrin MKJ, Physick-Sheard PW, Kenney DG. How to perform transvenous electrical cardioversion in horses with atrial fibrillation. J Vet Cardiol 2005;7:109-119.
15. van Loon G, De Clercq D, Tavernier R, et al. Transient complete atrioventricular block following transvenous electrical cardioversion of atrial fibrillation in a horse. Vet J 2005;170:124-127.
16. De Clercq D, van Loon G, Schauvliege S, et al. Transvenous electrical cardioversion of atrial fibrillation in six horses using custom made cardioversion catheters. Vet J 2008;177:198-204.
17. Kochiadakis GE, Igoumenidis NE, Parthenakis FI, et al. Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol 1999;33:966-971.
18. van Loon G, Tavernier R, Duytschaever M, et al. Pacing induced sustained atrial fibrillation in a pony. Can J Vet Res 2000;64:254-258.
19. Verbesselt R, Tjandramaga TB. De Schepper PJ. High-performance liquid chromatographic determination of 12 antiarrhythmic drugs in plasma using solid-phase column extraction. Ther Drug Monit 1991;13:157-165.
20. Patteson MW, Gibs C, Wotton PR, et al. Echocardiographic measurements of cardiac dimensions and indices of cardiac function in normal adult thoroughbred horses. Equine Vet J Suppl 1995;19:18-27.
21. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol 2001;37:542-547.
22. Fuster V, Rydén LE, Canmon DS, et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice guidelines. Circulation 2006;114:e257-e354.
23. Arboix M, Puigdemont A, Moya A, et al. Pharmacokinetics of intravenous propafenone in patients with episodes of paroxysmal supraventricular tachycardia. Methods Find Exp Clin Pharmacol 1985;7:435-438.
24. Connolly SJ, Kates RE, Lebsack CS, et al. Clinical pharmacology of propafenone. Circulation 1983;68:589-596.
25. Hollmann M, Brode E, Hotz D, et al. Investigations on the pharmacokinetics of propafenone in man. Arzneimittelforschung 1983;33:763-770.
26. Puigdemont A, Lligona LL, Arboix M, et al. Pharmacokinetics of propafenone in the dog after single-dose intravenous administration. J Vet Pharmacol Ther 1987;10:351-353.
27. Puigdemont A, Riu JL, Guitart R, et al. Propafenone kinetics in the horse: comparative analysis of compartmental and noncompartmental models. J Pharmacol Methods 1990;23:79-85.
28. Steurer G, Weber H, Schnmidinger H, et al. Plasma propafenone concentration in the evaluation of anti-arrhythmic efficacy. Eur Soc Cardiol 1991;12:526-532.
29. Chan GLY, Axelson JE, Price JDE, et al. In vitro protein binding of propafenone in normal and uraemic human sera. Eur J Clin Pharmacol 1989;36:495-499.
30. Karagueuzian HS, Fujimoto T, Katoh T, et al. Suppression of ventricular arrhythmias by propafenone, a new antiarrhythmic agent, during acute myocardial infarction in the conscious dog. A comparative study with lidocaine. Circulation 1982;66:1190-1198.
31. Clarot F, Goullé JP, Horst M, et al. Fatal propafenone overdoses: case reports and a review of the literature. J Anal Toxicol 2003;27:595-599.
32. Reef VB. Arrhythmias. In: Marr C, ed. Cardiology of the horse. London: WB Saunders Co, 1999;177-209.
33. Allessie MA, Wijffels MC, Dorland R. Mechanisms of pharmacologic cardioversion of atrial fibrillation by class I drugs. J Cardiovasc Electrophysiol 1998;9:S69-S77.
34. Spinler SA, Elder CA, Kindwall KE. Propafenone-induced liver injury. Ann Pharacother 1992;26:926-928.
35. Cocozzella D, Curciarello J, Corallini O, et al. Propafenone toxicity: report of two new cases. Dig Dis Sci 2003;48:354-357.
36. Gandolfi A, Rota E, Zanghieri G, et al. Acute cholestatic hepatitis caused by propafenone. Report of a case and review of the literature [in Italian]. Recenti Prog Med 2001;92:197-199.
37. Odeh M, Seligmann H, Oliven A. Propafenone-induced ataxia: report of three cases. Am J Med Sci 2000;320:151-153.
38. Huang YM, Lee WR, Hu CH, et al. Propafenone-induced acute generalized exanthematous pustulosis. Int J Dermatol 2005;44:256-257.
39. Wiesfeld ACP, Ansink JM, van Veldhuisen DJ, et al. Broad complex tachycardia during treatment of atrial fibrillation with a Ic antiarrhythmic drug: ventricular or supraventricular proarrhythmia? Int J Cardiol 2006;107:140-141.
40. Brubacher J. Bicarbonate therapy for unstable propafenone-induced wide complex tachycardia. CJEM 2004;6:349-356.
41. Stancak B, Markovic P, Rajnic A, et al. Acute toxicity of propafenone in a case of suicidal attempt. Bratisl Lek Listy 2004;105:14-17.
42. Unal S, Bayrackci B, Yasar U, et al. Successful treatment of propafenone, digoxin and warfarin overdosage with plasma exchange therapy and rifampicin. Clin Drug Investig 2007;27:505-508.